| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Sep 7, 2017 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 16,439 | $37.50 | $616,462.50 | -1.0% | |
| Sep 7, 2017 | PRGO Perrigo Co Plc | Wesolowski John | EVP, President Rx | Sell | 202 | $82.39 | $16,619.99 | -19.2% | |
| Sep 7, 2017 | PRGO Perrigo Co Plc | Kochan Sharon | EVP, Gm International | Sell | 318 | $81.36 | $25,873.66 | -1.5% | |
| Sep 7, 2017 | LNTH Lantheus Holdings, Inc. | Burgstahler David F | Director | Sell | 102,958 | $16.56 | $1,704,984.48 | -26.5% | |
| Sep 7, 2017 | SUPN Supernus Pharmaceuticals, Inc. | Schwabe Stefan K.F. | Executive Vice President R&D | Sell | 95,000 | $46.59 | $4,425,575.00 | -98.1% | |
| Sep 7, 2017 | PAHC Phibro Animal Health Corp | Johnson Richard G | Chief Financial Officer | Sell | 29,807 | $35.66 | $1,062,807.57 | -100% | |
| Sep 7, 2017 | PAHC Phibro Animal Health Corp | Miller Larry Lee | Chief Operating Officer | Sell | 32,459 | $35.59 | $1,155,110.56 | -100% | |
| Sep 6, 2017 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 20,393 | $60.00 | $1,223,580.00 | -21.8% | |
| Sep 6, 2017 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 100 | $60.00 | $6,000.00 | -0.8% | |
| Sep 6, 2017 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 4,607 | $60.00 | $276,420.00 | -5.9% | |
| Sep 6, 2017 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 26,250 | $60.00 | $1,575,000.00 | -9.2% | |
| Sep 6, 2017 | LNTH Lantheus Holdings, Inc. | Burgstahler David F | Director | Sell | 78,833 | $16.95 | $1,336,384.37 | -5.9% | |
| Sep 5, 2017 | LNTH Lantheus Holdings, Inc. | Orlandi Cesare | Chief Medical Officer | Sell | 18,000 | $16.69 | $300,475.80 | -17.1% | |
| Sep 5, 2017 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 3,100 | $37.50 | $116,250.00 | -0.2% | |
| Sep 5, 2017 | NBIX Neurocrine Biosciences Inc | Obrien Christopher Flint | Chief Medical Officer | Sell | 52,817 | $57.50 | $3,036,977.50 | -51.9% | |
| Sep 5, 2017 | IRWD Ironwood Pharmaceuticals Inc | McHugh Julie53 | Director | Sell | 1,500 | $16.16 | $24,240.00 | -1.8% | |
| Sep 5, 2017 | IRWD Ironwood Pharmaceuticals Inc | Olanoff Lawrence S | Director | Sell | 2,000 | $16.15 | $32,300.00 | -5.7% | |
| Sep 1, 2017 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,500 | $50.77 | $76,155.00 | -15.8% | |
| Aug 31, 2017 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 180,000 | $81.06 | $14,590,080.00 | -0.1% | |
| Aug 31, 2017 | EBS Emergent Biosolutions Inc. | Abdun-Nabi Daniel | President &CEO | Sell | 15,000 | $37.21 | $558,150.00 | -6.8% | |
| Aug 31, 2017 | PRGO Perrigo Co Plc | Kochan Sharon | EVP, Gm International | Sell | 1,500 | $79.03 | $118,545.00 | -12.7% | |
| Aug 31, 2017 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 5,461 | $37.50 | $204,787.50 | -0.3% | |
| Aug 31, 2017 | LNTH Lantheus Holdings, Inc. | Burgstahler David F | Director | Sell | 230,685 | $17.25 | $3,979,679.97 | -11.6% | |
| Aug 30, 2017 | PRGO Perrigo Co Plc | Farrington Thomas | EVP And CIO | Sell | 616 | $76.90 | $47,370.40 | -18.4% | |
| Aug 30, 2017 | TXMD Therapeuticsmd, Inc. | Thompson Tommy G51 | Director | Buy | 5,000 | $5.99 | $29,950.00 | +0.7% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.